Genelux Corporation (GNLX) News

$GNLX On alert for News!? stay tuned..

$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html

$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe

$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY

GNLX under $3

Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html

$GNLX Technical chart
https://schrts.co/SjVYghqR

$GNLX Website : https://genelux.com/

GNLX under $3

$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical

GNLX new 52 week low

GNLX new 52 lo

GNLX new 52 lo

GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.